Meiler Johannes, Schuler Martin
Department of Medicine III, Johannes Gutenberg University, Langenbeckstrasse 1, D-55131 Mainz, Germany.
Curr Drug Targets. 2006 Oct;7(10):1361-9. doi: 10.2174/138945006778559175.
Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
程序性细胞死亡(凋亡)是一种关键的肿瘤抑制机制。因此,大多数(即便不是所有)癌症都会形成消除或规避这一遗传程序的机制。除了促成恶性转化和肿瘤进展外,凋亡缺陷还会导致对细胞毒性癌症疗法产生抗性。在描绘导致凋亡的分子途径方面已取得了很大进展。这使得能够识别靶分子和先导化合物,以开发利用这种内在死亡程序来治疗癌症的新型疗法。在此,我们综述了目前对凋亡信号转导途径的理解,以及针对淋巴瘤和其他癌症对其进行治疗性调控的策略。